BACKGROUND:Coronary artery calcification (CAC) is an independent predictor of cardiovascular disease. A preventive role for vitamin K in CAC progression has been proposed on the basis of the properties of matrix Gla protein (MGP) as a vitamin K-dependent calcification inhibitor. OBJECTIVE: The objective was to determine the effect of phylloquinone (vitamin K1) supplementation on CAC progression in older men and women. DESIGN:CAC was measured at baseline and after 3 y of follow-up in 388 healthy men and postmenopausal women; 200 received amultivitamin with 500 microg phylloquinone/d (treatment), and 188 received a multivitamin alone (control). RESULTS: In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively. In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less CAC progression in the phylloquinone group than in the control group (P = 0.03). Of those with preexisting CAC (Agatston score > 10), those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone (P = 0.04). Phylloquinone-associated decreases in CAC progression were independent of changes in serum MGP. MGP carboxylation status was not determined. CONCLUSIONS:Phylloquinone supplementation slows the progression of CAC in healthy older adults with preexisting CAC, independent of its effect on total MGP concentrations. Because our data are hypothesis-generating, further studies are warranted to clarify this mechanism. This trial was registered at clinicaltrials.gov as NCT00183001.
RCT Entities:
BACKGROUND:Coronary artery calcification (CAC) is an independent predictor of cardiovascular disease. A preventive role for vitamin K in CAC progression has been proposed on the basis of the properties of matrix Gla protein (MGP) as a vitamin K-dependent calcification inhibitor. OBJECTIVE: The objective was to determine the effect of phylloquinone (vitamin K1) supplementation on CAC progression in older men and women. DESIGN: CAC was measured at baseline and after 3 y of follow-up in 388 healthy men and postmenopausal women; 200 received a multivitamin with 500 microg phylloquinone/d (treatment), and 188 received a multivitamin alone (control). RESULTS: In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively. In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less CAC progression in the phylloquinone group than in the control group (P = 0.03). Of those with preexisting CAC (Agatston score > 10), those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone (P = 0.04). Phylloquinone-associated decreases in CAC progression were independent of changes in serum MGP. MGP carboxylation status was not determined. CONCLUSIONS:Phylloquinone supplementation slows the progression of CAC in healthy older adults with preexisting CAC, independent of its effect on total MGP concentrations. Because our data are hypothesis-generating, further studies are warranted to clarify this mechanism. This trial was registered at clinicaltrials.gov as NCT00183001.
Authors: Maros Ferencik; Raymond C Chan; Stephan Achenbach; Jennifer B Lisauskas; Stuart L Houser; Udo Hoffmann; Suhny Abbara; Ricardo C Cury; Brett E Bouma; Guillermo J Tearney; Thomas J Brady Journal: Radiology Date: 2006-07-20 Impact factor: 11.105
Authors: Leon J Schurgers; Kirsten J F Teunissen; Marjo H J Knapen; Martijn Kwaijtaal; Rob van Diest; Ad Appels; Chris P Reutelingsperger; Jack P M Cleutjens; Cees Vermeer Journal: Arterioscler Thromb Vasc Biol Date: 2005-06-16 Impact factor: 8.311
Authors: Axel Schmermund; Stephan Achenbach; Thomas Budde; Yuri Buziashvili; Andreas Förster; Guy Friedrich; Michael Henein; Gert Kerkhoff; Friedrich Knollmann; Valery Kukharchuk; Avijit Lahiri; Roman Leischik; Werner Moshage; Michael Schartl; Winfried Siffert; Elisabeth Steinhagen-Thiessen; Valentin Sinitsyn; Anja Vogt; Burkhard Wiedeking; Raimund Erbel Journal: Circulation Date: 2006-01-16 Impact factor: 29.690
Authors: Todd C Villines; Christos Hatzigeorgiou; Irwin M Feuerstein; Patrick G O'Malley; Allen J Taylor Journal: Coron Artery Dis Date: 2005-05 Impact factor: 1.439
Authors: Yadon Arad; Louise A Spadaro; Marguerite Roth; David Newstein; Alan D Guerci Journal: J Am Coll Cardiol Date: 2005-07-05 Impact factor: 24.094
Authors: Rozemarijn Vliegenthart; Matthijs Oudkerk; Albert Hofman; Hok-Hay S Oei; Wim van Dijck; Frank J A van Rooij; Jacqueline C M Witteman Journal: Circulation Date: 2005-07-11 Impact factor: 29.690
Authors: M Kyla Shea; Kathryn Barger; Sarah L Booth; Gregory Matuszek; Mary Cushman; Emelia J Benjamin; Stephen B Kritchevsky; Daniel E Weiner Journal: Am J Clin Nutr Date: 2020-06-01 Impact factor: 7.045
Authors: Georg Schlieper; Ralf Westenfeld; Thilo Krüger; Ellen C Cranenburg; Elke J Magdeleyns; Vincent M Brandenburg; Zivka Djuric; Tatjana Damjanovic; Markus Ketteler; Cees Vermeer; Nada Dimkovic; Jürgen Floege; Leon J Schurgers Journal: J Am Soc Nephrol Date: 2011-02 Impact factor: 10.121
Authors: Jennifer T Truong; Xueyan Fu; Edward Saltzman; Ala Al Rajabi; Gerard E Dallal; Caren M Gundberg; Sarah L Booth Journal: J Nutr Date: 2012-03-21 Impact factor: 4.798
Authors: M Kyla Shea; Caren M Gundberg; James B Meigs; Gerard E Dallal; Edward Saltzman; Makiko Yoshida; Paul F Jacques; Sarah L Booth Journal: Am J Clin Nutr Date: 2009-09-23 Impact factor: 7.045
Authors: M Kyla Shea; Sarah L Booth; Michael E Miller; Gregory L Burke; Haiying Chen; Mary Cushman; Russell P Tracy; Stephen B Kritchevsky Journal: Am J Clin Nutr Date: 2013-05-29 Impact factor: 7.045